Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

PubWeight™: 6.79‹?› | Rank: Top 1%

🔗 View Article (PMC 3483088)

Published in Sci Transl Med on December 07, 2011

Authors

Kristine B Patterson1, Heather A Prince, Eric Kraft, Amanda J Jenkins, Nicholas J Shaheen, James F Rooney, Myron S Cohen, Angela D M Kashuba

Author Affiliations

1: University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

Articles citing this

(truncated to the top 100)

Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29

Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31

Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr (2013) 2.13

Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses (2013) 1.76

Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73

Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 1.68

Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51

Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49

Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One (2012) 1.42

Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med (2012) 1.36

Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS (2015) 1.30

Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc (2015) 1.27

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis (2016) 1.26

Does ART prevent HIV transmission among MSM? AIDS (2012) 1.20

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (2016) 1.20

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (2013) 1.19

Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol (2012) 1.15

Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses (2012) 1.14

Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS (2012) 1.13

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One (2012) 1.12

Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One (2014) 1.09

Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS (2013) 1.08

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses (2015) 1.08

Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr (2013) 1.07

Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep (2015) 1.04

Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. J Acquir Immune Defic Syndr (2013) 1.04

Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther (2012) 1.02

Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr (2012) 1.01

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One (2014) 1.00

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99

Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retroviruses (2013) 0.98

Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Res Treat (2012) 0.96

Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? BMC Med (2013) 0.96

Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol (2014) 0.95

Preventing HIV infection in women. J Acquir Immune Defic Syndr (2013) 0.95

Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol (2015) 0.95

Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis (2013) 0.94

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr (2015) 0.93

Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93

Mapping antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q Exactive and comparison with LC-MS/MS SRM assay. J Am Soc Mass Spectrom (2014) 0.93

Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One (2013) 0.93

Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet (2012) 0.91

Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs (2015) 0.90

The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS (2016) 0.90

Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89

Biomedical prevention: state of the science. Clin Infect Dis (2014) 0.89

Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture. PLoS One (2014) 0.88

HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol (2015) 0.88

Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr (2012) 0.87

Models for predicting effective HIV chemoprevention in women. J Acquir Immune Defic Syndr (2015) 0.87

Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis (2015) 0.87

HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology (2014) 0.87

Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc (2016) 0.87

Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. J Clin Pharmacol (2015) 0.86

Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet (2014) 0.86

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner. EBioMedicine (2015) 0.86

Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85

Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr (2015) 0.84

Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques. J Infect Dis (2013) 0.83

Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy. J Virol (2015) 0.83

Short communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract. AIDS Res Hum Retroviruses (2014) 0.83

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses (2016) 0.83

Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.82

Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. J Antimicrob Chemother (2014) 0.82

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82

Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV (2017) 0.82

Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS (2016) 0.81

Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. Expert Opin Pharmacother (2013) 0.81

Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health (2012) 0.81

Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. J Acquir Immune Defic Syndr (2016) 0.80

Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts. J AIDS Clin Res (2015) 0.79

A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses (2012) 0.79

Investigational reverse transcriptase inhibitors for the treatment of HIV. Expert Opin Investig Drugs (2015) 0.78

HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study. PLoS One (2012) 0.78

Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. J Acquir Immune Defic Syndr (2016) 0.78

Emtricitabine Seminal Plasma and Blood Plasma Population Pharmacokinetics in HIV-Infected Men in the EVARIST ANRS-EP 49 Study. Antimicrob Agents Chemother (2015) 0.78

Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. Antimicrob Agents Chemother (2015) 0.78

PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials. J Acquir Immune Defic Syndr (2016) 0.78

Pharmacology supports on-demand PrEP. Lancet HIV (2016) 0.77

HIV PrEP Trials: The Road to Success. Clin Investig (Lond) (2013) 0.77

Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? Artif Cells Nanomed Biotechnol (2014) 0.77

Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? J Int AIDS Soc (2015) 0.77

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infect Dis Ther (2016) 0.76

Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing. Biochem Pharmacol (2016) 0.76

Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS (2016) 0.76

Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial. AIDS Behav (2014) 0.76

Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. AIDS (2014) 0.76

HIV pre-exposure prophylaxis for women. J Virus Erad (2016) 0.75

Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies. PLoS One (2014) 0.75

Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates-proof of concept for HIV mucosal pre-exposure prophylaxis. Drug Deliv Transl Res (2016) 0.75

Barriers to a cure for HIV in women. J Int AIDS Soc (2016) 0.75

Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. Antimicrob Agents Chemother (2016) 0.75

PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS One (2016) 0.75

Oral PrEP for HIV prevention. It works. J Virus Erad (2015) 0.75

Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients. Antimicrob Agents Chemother (2016) 0.75

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91

Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85

Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89

Acute HIV-1 Infection. N Engl J Med (2011) 4.84

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr (2005) 3.33

Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol (2007) 2.03

Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis (2008) 1.91

The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55

Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention. J Med Primatol (2007) 1.48

HIV-1 transmission in the male genital tract. Am J Reprod Immunol (2010) 1.35

A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. J Chromatogr Sci (2008) 1.33

A new rectal model for dosimetry applications. J Nucl Med (1999) 1.23

Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.07

Articles by these authors

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48

Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50

Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30

Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60

Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14

The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22

American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93

The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87

Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85

Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76

Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66

Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40

Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89

HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54

AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21

Quality indicators for colonoscopy. Gastrointest Endosc (2014) 4.17

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointest Endosc (2010) 3.74

Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68

Surplus men, sex work, and the spread of HIV in China. AIDS (2005) 3.64

A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48

HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39

Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis (2006) 3.17

Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16

Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol (2007) 2.94

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91

American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.79

Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol (2012) 2.70

Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58

Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol (2009) 2.53

American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50

HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. J Acquir Immune Defic Syndr (2011) 2.49

Influence of race and gender on the presentation of eosinophilic esophagitis. Am J Gastroenterol (2011) 2.47

Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46

Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis (2006) 2.44

Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med (2012) 2.40

Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 2.38

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32

The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis (2005) 2.31

Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen. Sex Transm Dis (2006) 2.31

Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30

Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 2.28

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27

China's syphilis epidemic: a systematic review of seroprevalence studies. Sex Transm Dis (2006) 2.23

American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.23

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr (2007) 2.17

Prevalence of HIV infection among young adults in the United States: results from the Add Health study. Am J Public Health (2006) 2.17

Digestive and liver diseases statistics, 2004. Gastroenterology (2004) 2.14

Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect Dis (2010) 2.13

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One (2011) 2.06

Quality indicators for colonoscopy. Am J Gastroenterol (2014) 2.06

Keep them in school: the importance of education as a protective factor against HIV infection among young South African women. Int J Epidemiol (2008) 2.00

Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis (2005) 1.95

A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology (2009) 1.95

Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS (2007) 1.89

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One (2012) 1.84

Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82

Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc (2010) 1.79

HIV incidence among men who have sex with men in China: a meta-analysis of published studies. PLoS One (2011) 1.79

Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77

Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet (2009) 1.77

Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol (2013) 1.75

Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73

Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol (2003) 1.73

Inter- and intraobserver reliability and validation of a new method for determination of eosinophil counts in patients with esophageal eosinophilia. Dig Dis Sci (2009) 1.70

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis (2011) 1.70

Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68

Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia. Gastrointest Endosc (2012) 1.67

Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.67

A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67

Reduced polyp detection as endoscopy shift progresses: experience with screening colonoscopy at a tertiary-care hospital. J Clin Gastroenterol (2011) 1.66

Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology (2012) 1.65